Want to see JP:4889 full AI Analyst Report?
Renascience Inc. (4889) AI Stock Analysis
Renascience Inc.
(TSE/TYO:4889)
The score is held down primarily by weak financial performance—declining revenue, recurring losses, and persistent negative free cash flow—despite an improved, low-leverage balance sheet. Technicals also detract as the stock trades below all key moving averages with negative momentum, while valuation support is limited because earnings are negative and there is no dividend.
Renascience Inc. (4889) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 13.38B
- Dividend Yield
- ―
- Average Volume (3M)
- 313.14K
- Price to Earnings (P/E)
- -40.3
- Beta (1Y)
- 0.82
- Revenue Growth
- -33.24%
- EPS Growth
- -581.78%
- Country
- Japan
- Employees
- 3
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Renascience Inc. Business Overview & Revenue Model
Company Description
Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached...
Renascience Inc. Financial Statement Overview
Summary
Financials are weak overall: revenue is volatile and fell sharply in the latest year, profitability is structurally negative in most years, and operating/free cash flow are consistently negative (persistent cash burn). The main offset is a stronger balance sheet with zero debt by 2026, but returns remain inconsistent and often negative.
Income Statement
28NegativeBalance Sheet
63PositiveCash Flow
24Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 68.55M | 68.55M | 132.69M | 194.16M | 100.55M | 139.33M |
| Gross Profit | 64.21M | 64.21M | 128.95M | 165.64M | 100.30M | 77.60M |
| EBITDA | -335.12M | -356.88M | 143.82M | -250.50M | -332.49M | -244.65M |
| Net Income | -316.44M | -301.28M | 113.43M | -258.33M | -335.80M | -254.29M |
Balance Sheet | ||||||
| Total Assets | 3.29B | 3.50B | 1.87B | 2.09B | 2.27B | 2.44B |
| Cash, Cash Equivalents and Short-Term Investments | 3.20B | 3.40B | 1.80B | 2.03B | 2.21B | 2.39B |
| Total Debt | 0 | 0 | 0 | 356.10M | 309.60M | 199.23M |
| Total Liabilities | 53.15M | 180.59M | 151.21M | 482.11M | 409.76M | 237.17M |
| Stockholders Equity | 3.24B | 3.32B | 1.72B | 1.61B | 1.87B | 2.20B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -291.31M | -177.14M | -232.10M | -286.87M | -231.66M |
| Operating Cash Flow | 0 | -291.31M | -176.34M | -230.52M | -284.64M | -230.49M |
| Investing Cash Flow | 0 | 0 | 382.15M | -1.57M | 232.00K | -296.00K |
| Financing Cash Flow | 0 | 1.89B | -52.18M | 46.50M | 110.37M | 1.59B |
Renascience Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4889, the sentiment is Negative. The current price of 971.00 is below the 20-day moving average (MA) of 1022.25, below the 50-day MA of 1144.30, and below the 200-day MA of 1464.02, indicating a bearish trend. The MACD of -48.61 indicates Negative momentum. The RSI at 34.62 is Neutral, neither overbought nor oversold. The STOCH value of 52.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4889.
Renascience Inc. Peers Comparison
Overall Rating
JP:459348Neutral
JP:497842Neutral
JP:777442Neutral- JP:488941Neutral
JP:459940Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4978 | 42Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:4889 | 41Neutral | JPY 13.38B | -40.32 | ― | ― | -33.24% | -581.78% |
| JP:4599 | 40Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4889 | Renascience Inc. | 971.00 | -952.00 | -49.51% | |
| JP:4593 | Healios KK | 273.00 | -221.00 | -44.74% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 11, 2026